ANGN News and Press, Angion Biomedica Corp. From 08/15/22

Angion Biomedica press release ( NASDAQ: ANGN ): Q2 GAAP EPS of -$0.30. Revenue of $0.7M misses by $0.08M . For further details see: Angion Biomedica GAAP EPS of -$0.30, revenue of $0.7M misses by $0.08M

UNIONDALE, N.Y. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today provided a corporate update and...

Angion Biomedica ( NASDAQ: ANGN ) on Monday said it had started a process to evaluate strategic alternatives, including a merger or a sale of assets. The announcement comes after the biopharmaceutical company in late June said it would discontinue its phase 2 JUNIPER trial...

UNIONDALE, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced it has commenced a process to ...

Stifel has cut Angion Biomedica to neutral from buy following the company's decision to discontinue a phase 2 trial evaluating ANG-3070 for kidney diseases . Shares are down 36% in Thursday morning trading. The firm cut its price target to $1.50 from $5 (~12% downside ...

Gainers: NeuroSense Therapeutics ( NRSN ) +53% . Rapid Micro Biosystems ( RPID ) +36% . Burning Rock Biotech ( BNR ) +15% . Tyra Biosciences ( TYRA ) +7% . Addex Therapeutics ( ADXN ) +5% . Losers: Renalytix ( RNLX ) -40% ...

Renalytix ( RNLX ) -28% on Q3 earnings release . Angion Biomedica ( ANGN ) -27% after it discontinued phase 2 trial of ANG-3070 in patients with kidney disease . Exicure ( XCUR ) -23% as it implements reverse-stock-split to get back Nasdaq com...

Angion Biomedica ( NASDAQ: ANGN ) on Wednesday said it would discontinue its phase 2 JUNIPER trial evaluating its inhibitor ANG-3070 for the treatment of kidney diseases. The trial is being discontinued based upon a reassessment of the risk/benefit profile of ANG-3070 ...

UNIONDALE, N.Y., June 29, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced the discontinuation of JUNIPER...

Applied Therapeutics ( APLT ) -22% on pricing $30M equity offering . Xenon Pharmaceuticals ( XENE ) -13% on pricing $250M equity offering . Clovis Oncology ( CLVS ) -10% Zai Lab ( ZLAB ) -9% on conversion of secondary listing in Ho...